Phenotypic diversity of B cells in patients with chronic hepatitis C and its association with virus genotype (before and after therapy with direct-acting antivirals)

Q4 Medicine

Infektsionnye Bolezni Pub Date : 2022-01-01 DOI:10.20953/1729-9225-2022-1-74-81

A. Savchenko, E. P. Tikhonova, V. Belenjuk, A. Anisimova, A. Borisov

{"title":"Phenotypic diversity of B cells in patients with chronic hepatitis C and its association with virus genotype (before and after therapy with direct-acting antivirals)","authors":"A. Savchenko, E. P. Tikhonova, V. Belenjuk, A. Anisimova, A. Borisov","doi":"10.20953/1729-9225-2022-1-74-81","DOIUrl":null,"url":null,"abstract":"Objective. To analyze the phenotype of B-lymphocytes in patients with chronic infection with hepatitis C virus (HCV) before and after treatment with direct-acting antivirals (DAAs) depending on the virus genotype. Patients and methods. This open-label clinical and immunological study included 111 HCV patients with a mean age of 43.4 ± 8.6 years who received DAAs: Sofosbuvir (400 mg) and Velpatasvir (100 mg) once a day for 12 weeks. We assessed the phenotypic diversity of B-lymphocytes in peripheral blood of HCV patients during therapy and after its completion depending on the virus genotype. Results. Prior to DAA initiation, HCV patients demonstrated elevated count of CD19+CD5+CD27+ B cells and CD23+ B cells along with a decreased count of CD19+CD5–CD27+ B cells compared to controls. After therapy with DAAs, HCV patients continued to have increased proportion of CD19+CD5+CD27+ cells and reduced proportion of CD19+CD5–CD27+ cells. Conclusion. The pretreatment phenotypic diversity of peripheral B cells in HCV patents did not depend on the HCV genotype and was characterized by increased levels of B1 memory cells and activated B cells of the main subpopulations, along with a decreased level of B2 memory cells. The changes in the count of different B-cell subpopulations after DAA therapy depend on HCV genotype and might be associated with the rate of virus elimination. Key words: B-lymphocytes, immune system, direct-acting antivirals, chronic hepatitis C","PeriodicalId":37794,"journal":{"name":"Infektsionnye Bolezni","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infektsionnye Bolezni","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/1729-9225-2022-1-74-81","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective. To analyze the phenotype of B-lymphocytes in patients with chronic infection with hepatitis C virus (HCV) before and after treatment with direct-acting antivirals (DAAs) depending on the virus genotype. Patients and methods. This open-label clinical and immunological study included 111 HCV patients with a mean age of 43.4 ± 8.6 years who received DAAs: Sofosbuvir (400 mg) and Velpatasvir (100 mg) once a day for 12 weeks. We assessed the phenotypic diversity of B-lymphocytes in peripheral blood of HCV patients during therapy and after its completion depending on the virus genotype. Results. Prior to DAA initiation, HCV patients demonstrated elevated count of CD19+CD5+CD27+ B cells and CD23+ B cells along with a decreased count of CD19+CD5–CD27+ B cells compared to controls. After therapy with DAAs, HCV patients continued to have increased proportion of CD19+CD5+CD27+ cells and reduced proportion of CD19+CD5–CD27+ cells. Conclusion. The pretreatment phenotypic diversity of peripheral B cells in HCV patents did not depend on the HCV genotype and was characterized by increased levels of B1 memory cells and activated B cells of the main subpopulations, along with a decreased level of B2 memory cells. The changes in the count of different B-cell subpopulations after DAA therapy depend on HCV genotype and might be associated with the rate of virus elimination. Key words: B-lymphocytes, immune system, direct-acting antivirals, chronic hepatitis C

查看原文本刊更多论文

慢性丙型肝炎患者B细胞表型多样性及其与病毒基因型的关系（直接作用抗病毒药物治疗前后）

目标。目的分析慢性丙型肝炎病毒(HCV)感染患者直接抗病毒药物(DAAs)治疗前后不同病毒基因型的b淋巴细胞表型。患者和方法。这项开放标签临床和免疫学研究纳入了111名平均年龄为43.4±8.6岁的HCV患者，他们接受daa治疗:Sofosbuvir (400 mg)和Velpatasvir (100 mg)，每天一次，持续12周。我们评估了HCV患者在治疗期间和治疗结束后外周血b淋巴细胞的表型多样性，这取决于病毒基因型。结果。在DAA启动之前，与对照组相比，HCV患者表现出CD19+CD5+CD27+ B细胞和CD23+ B细胞计数升高，CD19+CD5 - CD27+ B细胞计数降低。在接受DAAs治疗后，HCV患者的CD19+CD5+CD27+细胞比例继续增加，CD19+CD5 - CD27+细胞比例继续降低。结论。HCV患者外周血B细胞预处理表型多样性不依赖于HCV基因型，主要亚群中B1记忆细胞和活化B细胞水平升高，B2记忆细胞水平降低。DAA治疗后不同b细胞亚群计数的变化取决于HCV基因型，并可能与病毒清除率有关。关键词:b淋巴细胞，免疫系统，直接抗病毒药物，慢性丙型肝炎

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infektsionnye Bolezni Medicine-Infectious Diseases

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： The journal publishes original research works, reviews of literature, lectures, methodological recommendations, clinical observations. Main topics: problems of etiology, pathogenesis, clinical manifestations of infectious diseases, new techniques and methods of their diagnosis, prevention and treatment; special attention is paid to the problems of antibacterial and antiviral therapy, the use of immunoglobulins and interferons, and also to intensive therapy of critical states. The journal is in the List of leading scientific journals and periodicals of the Supreme Attestation Committee, where the principal results of doctoral dissertations should be published.